Stage-resolved cytokine profiling nominates IL-17 as a prognostic node in relapsed/refractory B-cell lymphoma.
Findings indicate that IL-17 may be a potential biomarker with stage-specific clinical associations in B-NHL and warrants further investigation for risk stratification and individualized treatment monitoring.